PHARMACYTE BIOTECH INC (PMCB) Fundamental Analysis & Valuation

NASDAQ:PMCB • US71715X2036

Current stock price

0.672 USD
-0.01 (-1.37%)
At close:
0.6988 USD
+0.03 (+3.99%)
After Hours:

This PMCB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. PMCB Profitability Analysis

1.1 Basic Checks

  • PMCB had negative earnings in the past year.
  • PMCB had a negative operating cash flow in the past year.
  • In the past 5 years PMCB reported 4 times negative net income.
  • In the past 5 years PMCB always reported negative operating cash flow.
PMCB Yearly Net Income VS EBIT VS OCF VS FCFPMCB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M 20M

1.2 Ratios

  • PMCB's Return On Assets of -13.40% is fine compared to the rest of the industry. PMCB outperforms 79.50% of its industry peers.
  • The Return On Equity of PMCB (-19.00%) is better than 82.01% of its industry peers.
Industry RankSector Rank
ROA -13.4%
ROE -19%
ROIC N/A
ROA(3y)2.56%
ROA(5y)-9%
ROE(3y)-1.51%
ROE(5y)-12.48%
ROIC(3y)N/A
ROIC(5y)N/A
PMCB Yearly ROA, ROE, ROICPMCB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for PMCB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PMCB Yearly Profit, Operating, Gross MarginsPMCB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. PMCB Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, PMCB has less shares outstanding
  • Compared to 5 years ago, PMCB has more shares outstanding
  • PMCB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PMCB Yearly Shares OutstandingPMCB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M
PMCB Yearly Total Debt VS Total AssetsPMCB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

2.2 Solvency

  • Based on the Altman-Z score of -2.15, we must say that PMCB is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of PMCB (-2.15) is comparable to the rest of the industry.
  • PMCB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.15
ROIC/WACCN/A
WACCN/A
PMCB Yearly LT Debt VS Equity VS FCFPMCB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M 40M 60M 80M

2.3 Liquidity

  • A Current Ratio of 12.33 indicates that PMCB has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 12.33, PMCB belongs to the top of the industry, outperforming 86.07% of the companies in the same industry.
  • PMCB has a Quick Ratio of 12.33. This indicates that PMCB is financially healthy and has no problem in meeting its short term obligations.
  • PMCB has a better Quick ratio (12.33) than 86.07% of its industry peers.
Industry RankSector Rank
Current Ratio 12.33
Quick Ratio 12.33
PMCB Yearly Current Assets VS Current LiabilitesPMCB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. PMCB Growth Analysis

3.1 Past

  • The earnings per share for PMCB have decreased strongly by -195.65% in the last year.
EPS 1Y (TTM)-195.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.61%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PMCB Yearly EPS VS EstimatesPMCB Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2022 -10 -20 -30

More info and screens

Find the best growth stocksShow best growing peers

0

4. PMCB Valuation Analysis

4.1 Price/Earnings Ratio

  • PMCB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PMCB Price Earnings VS Forward Price EarningsPMCB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PMCB Per share dataPMCB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PMCB Dividend Analysis

5.1 Amount

  • No dividends for PMCB!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PMCB Fundamentals: All Metrics, Ratios and Statistics

PHARMACYTE BIOTECH INC

NASDAQ:PMCB (4/9/2026, 8:00:01 PM)

After market: 0.6988 +0.03 (+3.99%)

0.672

-0.01 (-1.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-16
Earnings (Next)08-10
Inst Owners9.71%
Inst Owner Change0%
Ins Owners3.45%
Ins Owner Change86.87%
Market Cap7.22M
Revenue(TTM)N/A
Net Income(TTM)-7.49M
Analysts43.33
Price TargetN/A
Short Float %0.96%
Short Ratio0.5
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.18
P/tB 0.19
EV/EBITDA N/A
EPS(TTM)-1.05
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.45
FCFYN/A
OCF(TTM)-0.45
OCFYN/A
SpS0
BVpS3.67
TBVpS3.52
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -13.4%
ROE -19%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)2.56%
ROA(5y)-9%
ROE(3y)-1.51%
ROE(5y)-12.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.33
Quick Ratio 12.33
Altman-Z -2.15
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-195.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.61%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-19.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-127.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-127.86%
OCF growth 3YN/A
OCF growth 5YN/A

PHARMACYTE BIOTECH INC / PMCB Fundamental Analysis FAQ

What is the fundamental rating for PMCB stock?

ChartMill assigns a fundamental rating of 2 / 10 to PMCB.


Can you provide the valuation status for PHARMACYTE BIOTECH INC?

ChartMill assigns a valuation rating of 0 / 10 to PHARMACYTE BIOTECH INC (PMCB). This can be considered as Overvalued.


Can you provide the profitability details for PHARMACYTE BIOTECH INC?

PHARMACYTE BIOTECH INC (PMCB) has a profitability rating of 1 / 10.


How financially healthy is PHARMACYTE BIOTECH INC?

The financial health rating of PHARMACYTE BIOTECH INC (PMCB) is 7 / 10.